Open AccessNeoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors
Author(s) -
Jens Jakob,
Peter Hohenberger
Publication year - 2018
Publication title -
visceral medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.598
H-Index - 17
eISSN - 2297-475X
pISSN - 2297-4725
DOI - 10.1159/000493405
Subject(s) - medicine , gist , imatinib , perioperative , gastroenterology , neoadjuvant therapy , oncology , surgery , cancer , stromal cell , breast cancer , myeloid leukemia
Gastrointestinal stromal tumors (GIST) are rare malignant tumors in terms of incidence, and they are not linked to specific symptoms. Often, primary tumors, particularly of the stomach, rectum, or rectovaginal space, are quite large when detected, and multivisceral resection seems to be the treatment of choice as the mainstay of therapy is complete tumor removal. If a gain-of-function mutation in the KIT gene is present, drug therapy with receptor tyrosine kinase inhibitors (RTKIs) might significantly downstage primary GIST tumors.